Loading patent…
AssigneediaDexus, Inc.
InventorsJackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
Estimating the term…
Isolated antibodies and antigen binding fragments thereof directed against Ovrl 10 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovrl 10-expressing cancer cells and alleviating or treating an Ovrl 10-expressing cancer in a mammal. The anti-Ovrl 10 antibodies modulate Ovrl 10 function or internalize upon binding to Ovrl 10 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovrl 10 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovrl 10 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.
An isolated antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof competes for binding to Ovr110 with a reference antibody, said antibody or antigen binding fragment thereof comprising:
2-6. (canceled)
8-9. (canceled)
The antibody or antigen binding fragment thereof of claim 12, wherein the light chain variable region CDR1 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
The antibody or antigen binding fragment thereof of claim 12, wherein the light chain variable region CDR2 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
An isolated monoclonal antibody or antigen binding fragment thereof which binds to Ovr110, said antibody or antigen binding fragment thereof comprising:
14-30. (canceled)
38-40. (canceled)
A method for preparing an anti-Ovr110 antibody comprising:
55-56. (canceled)
(canceled)
61-62. (canceled)
(canceled)
Dependencies are inferred from the claim text.